SITUATION REPORT

Nigeria Centre for Disease Control and Prevention

NCDC.GOV.NG

PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA TOLL FREE CALL: 6232 E:info@ncdc.gov.ng

@NCDCgov 🖪 🛩 🗿

TITLE:	UPDATE ON MPOX (MPX) IN NIGERIA
SERIAL NUMBER:	14
EPI-WEEK:	14
DATE:	April 9, 2023

Table 1 – Key Indicators

Reporting Year	Reporting week	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023 Current	Week 14	26	0	0	0.0	0	0
2023 Cumulative	Week 14	547	70	2	3.0	18 +FCT	51
2022 Cumulative	Week 14	41	13	0	0.0	6 + FCT	8

Highlights

- In week 14, the number of new suspected cases is 26, compared with 28 cases reported in week 13, 2023. These were reported from thirteen (13) states Ondo (6), Niger (3), Osun (3), Abia (2), Nasarawa (2), Ogun (2), Taraba (2), Anambra (1), Edo (1), Kano (1), Kwara (1), Yobe (1) and Zamfara (1) across 17 Local Government Areas.
- Since week 1 of 2023, eighteen (18) states and FCT have recorded at least one confirmed Mpox case across fifty-one (51) Local Government Areas. In 2023, the States with the highest burden are Lagos (30.0%), Ogun (12.8%), Abia (8.6%), Imo (5.7%) and Edo (5.7%), contributing 62.9% of confirmed cases.
- The number of confirmed cases is zero (0) in week 14, 2023, compared with four (4) confirmed cases reported in week 13, 2023.
- No death was recorded in week 14, with a CFR of 0.0% same as CFR of 0.0% that was reported in week 13, 2023.
- Overall, since the re-emergence of Mpox in September 2017, 3182 suspected cases have been reported from 36 states and FCT in the country. Of these 3156 suspected cases, 1058 (33.2%) were confirmed (with males predominantly affected) from 34 states and FCT. seventeen (17) deaths have been recorded since the re-emergence in 2017.
- The National Mpox multi-partner, multi-sectoral Technical Working Group (TWG) continues to coordinate the response activities at all levels.





CDC




Figure 1: Epidemic curve of suspected and confirmed Mpox cases January 2023 till date.




Figure 2: Age and sex distribution of Nigeria confirmed monkeypox cases from January 2023 till date.








Figure 3: Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2023 till date.

Figure 4: Area chart for States showing the trend in suspected and confirmed Mpox cases in highest burden States from January 2023 till date.










Figure 5: Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 9nd April 2023.

Table 1: Summary statistics for annual Nigeria Mpox cases by reporting year, September 2017 – 9 th April
2023

Reporting year	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023	547	70	2	3.0	18 +FCT	51
2022	2123	762	7	0.9	34 + FCT	238
2021	98	34	0	0.0	8 + FCT	25
2020	35	8	0	0.0	5	7
2019	65	47	1	2.1	11	26
2018	116	49	1	2.0	13	25
2017	198	88	6	6.8	14 + FCT	33

Table 2: Age distribution of cumulative number of confirmed Mpox cases September 2017 – 9th April 2023

0								
Age Group	2017	2018	2019	2020	2021	2022	2023	Total
0-10 Years	7	5	1	0	1	125	8	147
11-20 Years	12	4	1	0	4	123	6	150
21-30 Years	34	13	13	4	10	187	21	282
31- 40 Years	26	17	22	4	13	205	17	304
41-50 Years	9	10	9	0	5	89	14	136
> 50 Years	0	0	1	0	1	33	4	39
Total	88	49	47	8	34	762	70	1058







Table 3: Nigeria confirmed Mpox cases by State, September 2017 – 9th April 2023

S/N	State	2017	2018	2019	2020	2021	2022	2023	Total
1	Lagos	4	1	15	4	6	188	21	239
2	Rivers	25	14	7	1	5	37	3	92
3	Bayelsa	19	11	7	0	6	45	2	90
4	Abia	1	2	0	0	0	58	6	67
5	Delta	3	6	10	1	9	31	1	61
6	Imo	5	2	1	0	0	45	4	57
7	Ogun	0	0	0	0	1	40	9	50
8	Ondo	0	0	0	0	0	40	1	41
9	Edo	4	1	1	0	4	27	4	41
10	FCT	5	0	0	0	1	25	3	34
11	Anambra	0	1	1	0	0	25	0	27
12	Cross River	9	3	1	0	1	12	1	27
13	Kwara	0	0	0	0	0	21	0	21
14	Plateau	0	2	0	1	0	16	0	19
15	Akwa Ibom	6	0	1	0	0	12	3	22
16	Nasarawa	1	1	0	0	0	17	1	20
17	Adamawa	0	0	0	0	0	16	0	16
18	Оуо	1	3	2	0	0	10	1	10
19	Kaduna	0	0	0	0	0	15	2	17
20	Ebonyi	0	0	0	1	0	13	0	17
20	Benue	2	0	0	0	0	12	-	13
21				0	0	0	10	0	12
	Borno	0	0					2	
23	Enugu	1	2	1	0	0	4	3	11
24 25	Katsina Taraba	0	0	0	0	0	8 7	0	8
25	Kano	0	0	0	0	0	7	0	7
27	Gombe	0	0	0	0	0	6	0	6
28	Kogi	0	0	0	0	0	5	2	7
29	Osun	0	0	0	0	0	5	0	5
30	Ekiti	2	0	0	0	0	1	0	3
31	Niger	0	0	0	0	1	1	1	3
32	Kebbi	0	0	0	0	0	2	0	2
33	Bauchi	0	0	0	0	0	1	0	1
34	Zamfara	0	0	0	0	0	1	0	1
35	Yobe	0	0	0	0	0	1	0	1
	Grand Total	88	49	47	8	34	762	70	1058



Response activities

Pillar	Activities to date	Next steps			
Coordination	 Suppport strategic implementation of Mpox concept notes and budget Ensure liaison with all relevant stakeholders and partners across all pillars Provide subnational support to states on all Mpox activities Develop advocacy toolkits for field deployment 	 Deploy field support to high burden Mpox LGAs with poor Mpox sample management with the support of FAO 			
Surveillance	 Ensure data harmonization between surveillance, laboratory and case management pillars Key variables in the case investigation forms (sex, age, and date of symptoms onset) were missing from some reporting states Support weekly situation report development 	 Follow up with all reporting states on variable completeness and contact information on SORMAS Offsite support to data managers and surveillance notification officers on Mpox reporting tools 			
Laboratory	 Continuous testing of Mpox samples Offsites support to all states on appropriate sample collection, transportation and management 47% of samples met overall turnaround from NRL (time sample collected from states to time result shared to states) 	 Conduct training of States on Mpox Sample management 			

Notes on this report.

Data Source

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.

Case definitions

Suspected case

• An acute illness with fever >38.3°C, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed one to three days later by a progressively developing rash often beginning on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms of the hand.

Probable case

• A case that meets the clinical case definition is not laboratory-confirmed but has an epidemiological link to a confirmed case.

Confirmed case.

A clinically compatible case that is laboratory confirmed

Contact







• Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., contact with skin lesions, oral secretions, urine, faeces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

Calculations

• Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.







